Drug intelligence / Profile preview

AVX70481

Development stage: Phase 1
Lead developer: AstriVax Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AVX70481 is an investigational prophylactic vaccine developed by AstriVax for the prevention of rabies. It is currently being evaluated in a first-in-human, phase 1 clinical trial to assess its safety, reactogenicity, and immunogenicity in healthy adults. The vaccine utilizes a novel platform technology involving plasmids that deliver live-attenuated virus vectors along with the target viral antigen, designed to elicit strong and long-lasting immune responses with microdoses. This self-amplifying mechanism aims to provide robust protection against rabies infection and potentially offers advantages such as ease of production and limited cold chain requirements[1][4][8].

Other names: Rabies vaccine AstriVax

Beyond the preview

Go deeper on AVX70481.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVX70481.

Explore the full profile